KRT88P and hepatitis A virus infection: The use of B cell depleting monoclonal antibodies against CD20 (anti-CD20) such as rituximab was documented to significantly raise the risk of HBVr and hepatitis flare [34]; the negative impact of rituximab was also observed in HBsAg-negative antibody against hepatitis B core antigen (anti-HBc)-positive patients, including those who were seropositive for anti-HBs [32,33].